🇺🇸 FDA
Patent

US 11220496

Compounds and method for treating autoimmune diseases

granted A61KA61K31/506A61K31/675

Quick answer

US patent 11220496 (Compounds and method for treating autoimmune diseases) held by Rigel Pharmaceuticals, Inc. expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Jan 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/506, A61K31/675, A61K45/06, A61P